A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Regor Pharmaceuticals Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Kivu Bioscience Inc.
Genentech, Inc.
Evopoint Biosciences Inc.
Seagen Inc.
Bristol-Myers Squibb
Travera Inc
Eli Lilly and Company
OncoC4, Inc.
Kortuc, Inc.
Bayer
AstraZeneca
KaliVir Immunotherapeutics
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Arcus Biosciences, Inc.
AstraZeneca
Radiopharm Theranostics, Ltd
Agenus Inc.
Sotio Biotech Inc.
Radiopharm Theranostics, Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
AstraZeneca
SystImmune Inc.
Terremoto Biosciences Inc.
Rondo Therapeutics
Taiho Oncology, Inc.
Orano Med LLC
Timser SAPI de CV
GI Innovation, Inc.
Ensem Therapeutics
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Alterome Therapeutics, Inc.
MediLink Therapeutics (Suzhou) Co., Ltd.
Medtronic - MITG
Sutro Biopharma, Inc.
Timser SAPI de CV
Convalife (Shanghai) Co., Ltd.
Eli Lilly and Company
Neonc Technologies, Inc.
ViroMissile, Inc.
Seagen Inc.
Ascendis Pharma A/S